SIRT1/2 INHIBITOR IV
SIRT1/2 INHIBITOR IV 性质
| 熔点 | 235 °C(dec.) |
|---|---|
| 密度 | 1.41±0.1 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 二甲基亚砜：≥10mg/mL |
| 形态 | 白色固体 |
| 酸度系数(pKa) | 7.24±0.25(Predicted) |
| 颜色 | 白色至类白色 |
| InChI | 1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7-2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26) |
| InChIKey | RVNSQVIUFZVNAU-UHFFFAOYSA-N |
| SMILES | Oc1ccc2ccccc2c1CC3=C(NC(=S)NC3=O)c4ccccc4 |
SIRT1/2 INHIBITOR IV 用途与合成方法
| Target | Value |
|
nSMase2
(Cell-free assay) | 7 μM(Ki) |
Cambinol inhibits NAD-dependent deacetylase activity of human SIRT1 and SIRT2. Inhibition of SIRT1 activity with cambinol during genotoxic stress leads to hyperacetylation of key stress response proteins and promotes cell cycle arrest. Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induces apoptosis, which is accompanied by hyperacetylation of BCL6 and p53. Cambinol has only weak inhibitory activity against SIRT5 (42% inhibition at 300 μM) and no activity against SIRT3.
Cambinol is well tolerated in mice (100 mg/kg) and inhibits growth of Burkitt lymphoma xenografts. No significant weight loss occurs in cambinol-treated animals relative to controls. Inhibitors of NAD-dependent deacetylases may constitute novel anticancer agents.
SIRT1/2 INHIBITOR IV 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-06 | C3535 | Cambinol | 14513-15-6 | 5mg | 130 |
| 2026-06-06 | C3535 | Cambinol | 14513-15-6 | 25mg | 590 |
